CN103908604A - Preparation used for treating osteoarthritis and preparation method thereof - Google Patents
Preparation used for treating osteoarthritis and preparation method thereof Download PDFInfo
- Publication number
- CN103908604A CN103908604A CN201410180088.XA CN201410180088A CN103908604A CN 103908604 A CN103908604 A CN 103908604A CN 201410180088 A CN201410180088 A CN 201410180088A CN 103908604 A CN103908604 A CN 103908604A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- preparation
- glucosamine
- osteoarthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 14
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 12
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000706 filtrate Substances 0.000 claims abstract description 12
- 229960002442 glucosamine Drugs 0.000 claims abstract description 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- 241000196324 Embryophyta Species 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940032094 squalane Drugs 0.000 claims abstract description 5
- 241000628997 Flos Species 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 11
- 244000058281 Ulmus pumila Species 0.000 claims description 10
- 235000001547 Ulmus pumila Nutrition 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 5
- 235000011837 pasties Nutrition 0.000 claims description 5
- 241000792914 Valeriana Species 0.000 claims description 4
- 235000017468 valeriana Nutrition 0.000 claims description 4
- 235000019082 Osmanthus Nutrition 0.000 abstract description 3
- 241000333181 Osmanthus Species 0.000 abstract description 3
- 241000219305 Atriplex Species 0.000 abstract 2
- 241000209205 Coix Species 0.000 abstract 2
- 241000219784 Sophora Species 0.000 abstract 2
- 241000913745 Spatholobus Species 0.000 abstract 2
- 241000545405 Tripterygium Species 0.000 abstract 2
- 235000009499 Vanilla fragrans Nutrition 0.000 abstract 2
- 244000263375 Vanilla tahitensis Species 0.000 abstract 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 abstract 2
- 229930182470 glycoside Natural products 0.000 abstract 2
- 150000002338 glycosides Chemical class 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 15
- 208000006820 Arthralgia Diseases 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 210000004417 patella Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010005963 Bone formation increased Diseases 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000236488 Lepra Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- OUCXYSRPMBQONT-UHFFFAOYSA-N acetamide;phenol Chemical compound CC(N)=O.OC1=CC=CC=C1 OUCXYSRPMBQONT-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a preparation used for treating osteoarthritis. The preparation is prepared from spatholobus suberctu, tripterygium glycosides, sophora flower bud, sweet-scented osmanthus, atriplex, cortex acanthopanacis, vanilla, coix, squalane and glucosamine. The method for preparing the preparation used for treating osteoarthritis includes the following steps: a. respectively carting out heating reflux extraction on the spatholobus suberctu and the tripterygium glycosides twice by using 95% ethanol, 2 hours each time, mixing the extracting solutions, concentrating, evaporating to dryness and preparing powder; b. respectively preparing the sophora flower bud, the sweet-scented osmanthus and the atriplex into 300-500 meshes powder; c. adding the cortex acanthopanacis and the vanilla into 100 parts of water, decocting for half an hour, and taking filtrate; adding coix into the filtrate, heating into paste, drying and preparing powder; d. adding the powders prepared in step a, step b and step c into the squalane and the glucosamine, and stirring uniformly; and preparing plant capsules, wherein each capsule contains 0.68g of the drug.
Description
Technical field
The invention belongs to field of medicaments, be specially a kind of preparation that is used for the treatment of osteoarthritis and preparation method thereof.
Background technology
Osteoarthritis (osteoarthritis, OA) is a kind of chronic joint disease take Articular cartilage degeneration and Secondary cases hyperosteogeny as characteristic.Be more common in middle-aged and elderly people, women is more than male.Be apt to occur in the positions such as knee joint, hip joint, lumbosacral region joint of vertebral column (Lumbosacral joint) and a Plantar toe joint (First MIP joints) that heavy burden is larger, and the DIPJ of hand (DIP joints), proximal interphalangeal joint (PIP joints).This disease is also called osteoarthritis, degenerative osteoarthritis, hypertrophy row arthritis, osteoarthritis etc.Along with the aging and fat ratio of population rises, the prevalence rate of osteoarthritis will improve.
General treatement: often have a rest, want Saving cortilage, avoid violent, excessively and the activity of bearing a heavy burden (squat down, bend over, stair climbing, go on a journey, carry weight, climb the mountain), the support of will lying up when major injury fixedly prevents deformity.In addition, strengthen the muscle strength of joint periphery, reduce joint wearing and tearing; And disperse joint to bear a heavy burden through crutch, knee cap.Cross severe one and must control body weight, reduce joint burden.
Pharmacotherapy: acetyl ammonia phenol: be to process the First Line medication of pain, only have analgesic effect and without anti-inflammatory effect, but side effect is slighter.Oral or external on-steroidal anti-inflammation analgesic (NSAID): the most conventional, comprising: Naproxen, Salsalate, Ibuprofen, Diclofenac, can alleviate pain and reduce inflammation; Approximately there is 30% patient to take on-steroidal anti-inflammation analgesic and can produce upper digestive tract malaise symptoms, comprise dyspepsia, abdominal distention, feel sick, digestive tract hemorrhage, ulcer; In addition, likely can cause edema or affect renal function at fraction patient NSAID.Clinical research result shows, the slightly poor but various side effect much less of the effect of external NSAID, but still have the possibility of chafe.Joint inner injection hyaluronic acid (Hyaluronate), this is to supplement as visco-elastic material by its rheological behavior, effect is lubricated joint Saving cortilage cartilage.The inner injection in joint steroid: synovial capsule inflammation is the main cause of osteoarthritis pain, therefore the effectively pain relieving of local injection anti-inflammatory drug.But in clinical trial, although only than placebo group many about 2 weeks pretty good effect persistent period of the analgesic effect of steroid be therefore used at most short-term pain relieving.
Summary of the invention
The object of this invention is to provide a kind of preparation that is used for the treatment of osteoarthritis and preparation method thereof.
The preparation that is used for the treatment of osteoarthritis of the present invention; Crude drug by following parts by weight: 6～10 parts of 4～6 parts of Caulis Spatholobis, 5～9 parts of Radix Tripterygii Wilfordiis, 3～5 parts of the Flos Sophorae Immaturus, 4～6 parts of Flos Osmanthi Fragrantis, 8～12 parts of Ulmus pumila L., 7～10 parts of Cortex Acanthopanciss, 4～6 parts of Rhizoma et radix valerianaes, 7～9 parts of Semen Coiciss, 8～12 parts of squalanes, glucosamine are made.
As optimization, originally be used for the treatment of the preparation of osteoarthritis, the crude drug by following parts by weight: 9.5 parts of 5 parts of Caulis Spatholobis, 6 parts of Radix Tripterygii Wilfordiis, 3.5 parts of the Flos Sophorae Immaturus, 4 parts of Flos Osmanthi Fragrantis, 9 parts of Ulmus pumila L., 7 parts of Cortex Acanthopanciss, 4.5 parts of Rhizoma et radix valerianaes, 8 parts of Semen Coiciss, 10 parts of squalanes, glucosamine are made.
Preparation is originally used for the treatment of the method for osteoarthritis preparation, comprises the following steps:
A, the Caulis Spatholobi of described parts by weight, Radix Tripterygii Wilfordii are extracted to twice by 95% alcohol heating reflux respectively, each 2 hours, merge extractive liquid,, concentrated evaporate to dryness, powder process;
B, the Flos Sophorae Immaturus of described parts by weight, Flos Osmanthi Fragrantis, Ulmus pumila L. are made respectively to 300～350 object powder;
C, the Cortex Acanthopancis of described parts by weight, Rhizoma et radix valerianae are joined in 100 parts of water and decoct and get its filtrate half an hour; The Semen Coicis of described parts by weight is added in described filtrate, be heated to pasty state, dry powder process;
D, by the powder in step a, step b, step c; Join in the squalane, glucosamine of described parts by weight, stir; Be made into plant capsule according to 0.68 gram one.
The present invention is used for the treatment of in the preparation recipe of osteoarthritis,
Radix Tripterygii Wilfordii effect expelling wind and removing dampness, removing obstruction in the collateral to relieve pain, reducing swelling and alleviating pain, removing toxic substances parasite killing.For damp and hot tuberosity, the long-pending poison of carcinoma, treat lepra reaction, rheumatoid arthritis etc. with it clinically, there is the effect such as antitumor, antiinflammatory.
The Flos Sophorae Immaturus has cold, and sweet in the mouth is flat; Enter liver, large intestine channel.
Flos Sophorae Immaturus cooling blood for hemostasis, liver heat removing pathogenic fire reducing.Cure mainly discharging fresh blood stool, hemorrhoidal bleeding, hematuria, stranguria with blood, metrorrhagia, dysentery with red and white feces, conjunctival congestion, sore, the diseases such as hypertension.
Semen Coicis sweet in the mouth, light, cold nature.There are invigorating spleen to remove dampness, clearing away heat and discharging pus function.For diseases such as diarrhea due to hypofunction of the spleen edema beriberi, leucorrhea, wet, arthralgia, acute appendicitis, consumptive lung diseases.
Flos Osmanthi Fragrantis effect: yellowish white, fragrance, extracts aromatic oil, and osmanthus concrete processed, can be used for food, cosmetics, can cake processed, confection, and can make wine.Function cures mainly: flower: the broken knot of cold expelling, preventing phlegm from forming and stopping coughing.For toothache, cough with asthma abundant expectoration, amenorrhea stomachache.
Ulmus pumila L. is flat, and sweet in the mouth is micro-pungent; Enter lung, spleen, heart channel.There is spleen-benefiting mind-tranquilizing, clearing heart fire, relieving cough and resolving phlegm, clearing away heat and promoting diuresis, effect of parasite killing detumescence.Cure mainly insomnia, inappetence, leukorrhagia, dysuria, edema, children's's infantile malnutrition with fever weakness and emaciation, burn and scald, the diseases such as skin ulcer tinea.
Cortex Acanthopancis has wind-damp dispelling, invigorating the liver and kidney, the effects such as bone and muscle strengthening.Product also have the effects such as antitumor, resisting fatigue, reduction whole blood viscosity, atherosclerosis formation.
Caulis Spatholobi red complexion enters blood, and matter profit row is loose; There is relaxing muscles and tendons to promote blood circulation, effect of nourishing blood for regulating menstruation; Cure mainly rheumatic arthralgia, numb hand and foot, quadriplegia, menoxenia, blockage of menstruation, dysmenorrhea, amenorrhea, leukopenia.
Rhizoma et radix valerianae herb can be used as medicine, and the large temperature of property, enters Liver and kidney warp, the kidney warming sun, and lung moistening YIN nourishing, the Wen Han that dispels, has the kidney invigorating wind dispelling, supporing yang analgesic effect, has that refreshing people's body and mind, quiet brain are calmed the nerves, the effect of lax nerve, relieving fatigue, removing obstruction in the collateral to relieve pain, replenishing kidney-YIN tonifying YANG.
Squalane is pinch highly finished product that go out in the liver of the large-scale shark in abyssal environment, and the hydrocarbons being made up of the two keys of six isoprene, belongs to terpenoid structure.Squalene not only exists in shark liver, and is the internal substance in human body.Participate in vivo biosynthesis and the multiple biochemical reaction of gallbladder because of alcohol, promote the metabolism of biological oxidation and body, improve the defensive enginery of body, stress ability and body and mind quality, accelerate class because of alcohol hormone synthetic, the activity of activated adenyl cyclase, causes that second message,second messenger's Level of Camp increases.
Glucosamine is releived because the pain that arthritis causes, stiff and swelling osteoporosis make cartilage consume, finally causes cracked peeling off, and the buffering of cartilage has been lacked in joint, easily produces painful stiff and inflammation.And glucamine contributes to repair damaged cartilage, stimulate the generation of new cartilage, improve inflammation symptom, the arthralgia of releiving, stiff and swelling.
Various active components compatibility of the present invention, promoting blood circulation to remove obstruction in the collateral, the strong bone of QI invigorating, can effectively improve arthralgia and promote osteoarthrosis functional rehabilitation, promotes osteocyte propagation, differentiation; Treatment osteoarthritis effect is remarkable.Relevant clinical data is as follows.
Physical data: 800 routine knee osteoarthritis patients, one-sided 530 examples, bilateral 270 examples.Wherein male 290 examples, female's 510 examples; 41～66 years old age, average 53.33 years old.The course of disease 5 months～6 years., be divided at random treatment group 400 example and matched group 400 examples.
Diagnostic criteria: meet the definite OA diagnostic criteria of Americanism damp disease association; Knee joint osteoarthritis criteria for classification is as follows: the diagnosis of kneecap arthrosis: (1) front month most of time has gonalgia, (2) there is joint crepitus, (3) morning stiff time <30min, (4) in age >38 year, (5) have bone to expand.Meet 1+2+3+4 bar or 1+2+5 bar or 1+4+5 bar person and can make the diagnosis of kneecap arthrosis.Knee osteoarthritis diagnosis: (1) front month most of time has gonalgia, (2) hyperosteogeny forms, (3) joint fluid inspection meets osteoarthritis, (4) age <40 year, (5) morning stiff time <30min, (6) have bony crepitus.Meet ten persons of 1+2 bar or 1+3+5+6 bar or 1+4+5 and can make knee osteoarthritis diagnosis.
Therapeutic Method: matched group simple oral Drug therapy: loxoprofen sodium dispersible tablets, 1 tablet/time, three times on the one; Glucosamine hydrochloride capsule: 11 time, one day twice, 35 days courses for the treatment of.Treatment group is used the embodiment of the present invention 1 Chinese medicine, 3 times on the 1st, 1 time 2,35 days courses for the treatment of.
Efficacy evaluation: arthralgia: effective: detumescence, without arthralgia; Effective: pain is light, still can stand, or pain when fatigue or Changes in weather only, substantially do not affect work; Invalid: pain is heavier, working and having a rest is all affected, and need be used in conjunction with analgesic drug product.Articular pain: effective: joint is without tenderness; Effective: tenderness is lighter; Invalid: tenderness is obvious, pain can not be touched, endurable.The results are shown in Table 1.Adopt HSs scale to evaluate patient's osteoarthrosis functional rehabilitation situation, these scale full marks are 100, and wherein pain 3O divides, 22 points of functions, and 18 points of mobilities, muscular strength 1O divides, and lopsided 1O divides, and stability 1O divides, and score is higher shows that knee joint function is better.The results are shown in Table 2.
Result:
The specific embodiment
The invention will be further described for embodiment plan given below; but can not be interpreted as it is limiting the scope of the invention; according to the present invention, content, to nonessential improvement and adjustment more of the present invention, still belongs to protection scope of the present invention to those skilled in the art.
Embodiment 1, a, gets 6 grams of 5 grams of Caulis Spatholobis, Radix Tripterygii Wilfordii and respectively 95% alcohol heating reflux is extracted to twice, and each 2 hours, merge extractive liquid,, concentrated evaporate to dryness, powder process; B, get 9 grams of 3.5 grams of the Flos Sophorae Immaturus, 4 grams of Flos Osmanthi Fragrantis, Ulmus pumila L. and make respectively 300～350 object powder; C, get 4.5 grams of 7 grams of Cortex Acanthopanciss, Rhizoma et radix valerianae and join after decocting half an hour in 100 grams of water and get its filtrate; Get 8 grams of Semen Coiciss and add in described filtrate, be heated to pasty state, dry powder process; D, by the powder in step a, step b, step c; Be communicated with 9.5 grams of 10 grams of squalanes, glucosamine and join in blender and stir, be then made into plant capsule according to 0.68 gram one.
Embodiment 2, a, gets 5 grams of 4 grams of Caulis Spatholobis, Radix Tripterygii Wilfordii and respectively 95% alcohol heating reflux is extracted to twice, and each 2 hours, merge extractive liquid,, concentrated evaporate to dryness, powder process; B, get 8 grams of 3 grams of the Flos Sophorae Immaturus, 4 grams of Flos Osmanthi Fragrantis, Ulmus pumila L. and make respectively 300～350 object powder; C, get 4 grams of 7 grams of Cortex Acanthopanciss, Rhizoma et radix valerianae and join after decocting half an hour in 100 grams of water and get its filtrate; Get 7 grams of Semen Coiciss and add in described filtrate, be heated to pasty state, dry powder process; D, by the powder in step a, step b, step c; Be communicated with 6 grams of 8 grams of squalanes, glucosamine and join in blender and stir, be then made into plant capsule according to 0.68 gram one.
Embodiment 3, a, gets 9 grams of 6 grams of Caulis Spatholobis, Radix Tripterygii Wilfordii and respectively 95% alcohol heating reflux is extracted to twice, and each 2 hours, merge extractive liquid,, concentrated evaporate to dryness, powder process; B, get 12 grams of 5 grams of the Flos Sophorae Immaturus, 6 grams of Flos Osmanthi Fragrantis, Ulmus pumila L. and make respectively 300～350 object powder; C, get 6 grams of 10 grams of Cortex Acanthopanciss, Rhizoma et radix valerianae and join after decocting half an hour in 100 grams of water and get its filtrate; Get 9 grams of Semen Coiciss and add in described filtrate, be heated to pasty state, dry powder process; D, by the powder in step a, step b, step c; Be communicated with 10 grams of 12 grams of squalanes, glucosamine and join in blender and stir, be then made into plant capsule according to 0.68 gram one.
Claims (3)
1. one kind is used for the treatment of the preparation of osteoarthritis; It is characterized in that the crude drug by following parts by weight: 6～10 parts of 4～6 parts of Caulis Spatholobis, 5～9 parts of Radix Tripterygii Wilfordiis, 3～5 parts of the Flos Sophorae Immaturus, 4～6 parts of Flos Osmanthi Fragrantis, 8～12 parts of Ulmus pumila L., 7～10 parts of Cortex Acanthopanciss, 4～6 parts of Rhizoma et radix valerianaes, 7～9 parts of Semen Coiciss, 8～12 parts of squalanes, glucosamine are made.
2. the preparation that is used for the treatment of osteoarthritis according to claim 1, it is characterized in that the crude drug by following parts by weight: 9.5 parts of 5 parts of Caulis Spatholobis, 6 parts of Radix Tripterygii Wilfordiis, 3.5 parts of the Flos Sophorae Immaturus, 4 parts of Flos Osmanthi Fragrantis, 9 parts of Ulmus pumila L., 7 parts of Cortex Acanthopanciss, 4.5 parts of Rhizoma et radix valerianaes, 8 parts of Semen Coiciss, 10 parts of squalanes, glucosamine are made.
3. prepare a method that is used for the treatment of osteoarthritis preparation described in claim 1, it is characterized in that comprising the following steps:
A, the Caulis Spatholobi of described parts by weight, Radix Tripterygii Wilfordii are extracted to twice by 95% alcohol heating reflux respectively, each 2 hours, merge extractive liquid,, concentrated evaporate to dryness, powder process;
B, the Flos Sophorae Immaturus of described parts by weight, Flos Osmanthi Fragrantis, Ulmus pumila L. are made respectively to 300～350 object powder;
C, the Cortex Acanthopancis of described parts by weight, Rhizoma et radix valerianae are joined in 100 parts of water and decoct and get its filtrate half an hour; The Semen Coicis of described parts by weight is added in described filtrate, be heated to pasty state, dry powder process;
D, by the powder in step a, step b, step c; Join in the squalane, glucosamine of described parts by weight, stir; Be made into plant capsule according to 0.68 gram one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410180088.XA CN103908604B (en) | 2014-04-30 | 2014-04-30 | For preparation treating osteoarthritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410180088.XA CN103908604B (en) | 2014-04-30 | 2014-04-30 | For preparation treating osteoarthritis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103908604A true CN103908604A (en) | 2014-07-09 |
| CN103908604B CN103908604B (en) | 2016-08-24 |
Family
ID=51034808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410180088.XA Expired - Fee Related CN103908604B (en) | 2014-04-30 | 2014-04-30 | For preparation treating osteoarthritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103908604B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1342462A (en) * | 2000-09-08 | 2002-04-03 | 何兴峰 | Composite medicine for treating rheumatoid arthritis |
| CN103191212A (en) * | 2013-03-26 | 2013-07-10 | 鲁道宗 | Externally used traditional Chinese medicine powder for treating osteoarthritis and preparation method thereof |
-
2014
- 2014-04-30 CN CN201410180088.XA patent/CN103908604B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1342462A (en) * | 2000-09-08 | 2002-04-03 | 何兴峰 | Composite medicine for treating rheumatoid arthritis |
| CN103191212A (en) * | 2013-03-26 | 2013-07-10 | 鲁道宗 | Externally used traditional Chinese medicine powder for treating osteoarthritis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李荣亨等: "内服中药治疗骨关节炎用药概况", 《全国中西医结合强直性脊柱炎专题研讨会论文汇编》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103908604B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100423761C (en) | Chinese medicinal preparation for treating fracture, traumatic injury | |
| CN103656535A (en) | Chinese medicinal composition for treating hyperlipidemia and preparation method thereof | |
| CN101337059A (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
| CN103505659A (en) | Chinese proprietary medicine for treating rheumatoid arthritis | |
| CN101474288B (en) | Chinese medicine composition for treating wind-cold-dampness induced paralysis | |
| CN103083522B (en) | Traditional Chinese medicine composition for hair growing and hair nourishing, as well as preparation method and application thereof | |
| CN102940820B (en) | Traditional Chinese medicine composition for treating diarrhea | |
| CN103735647A (en) | Medicated wine for treating chronic infectious arthritis | |
| CN105412864A (en) | Pain relieving ointment for treating prolapse of lumbar intervertebral disc | |
| CN106540229A (en) | A kind of exterior-applied medical wine for treating cold pain disease and preparation method thereof | |
| CN106362066A (en) | Medicinal liquor for treatment of rheumatic and rheumatoid diseases and preparation method thereof | |
| CN105311210A (en) | Pharmaceutical composition for treating rheumatoid bone diseases | |
| CN101181487B (en) | Chinese medicine composition orally taken for curing osteosporosis | |
| CN103908604A (en) | Preparation used for treating osteoarthritis and preparation method thereof | |
| CN105687444A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method and application thereof | |
| CN105641330A (en) | Traditional Chinese medicine composition for invigorating kidney and strengthening yang | |
| CN105343675A (en) | Traditional Chinese medicine preparation for treating adiposis and preparation method thereof | |
| CN103989968A (en) | Oral traditional Chinese medicinal composition for treating cervical spinal stenosis | |
| CN103599321A (en) | Traditional Chinese medicine composition for treating osteoporosis | |
| CN102671143B (en) | Parslane herb Chinese medicinal oral liquid for treating dysentery and preparation method for parslane herb Chinese medicinal oral liquid | |
| CN1171967A (en) | Medicinal liquid Yuyepizhengke for curing rheumatic arthritis | |
| CN101095753A (en) | Chinese medicine preparation for treating diabetic hyperlipaemia | |
| CN105106834A (en) | Huoluo oil and preparation method thereof | |
| CN105106913A (en) | Traditional Chinese medicine composition for treating spleen-kidney yang deficiency type chronic colitis | |
| CN105288445A (en) | Medicine for treating cervical bone hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LI BAOJI Free format text: FORMER OWNER: ZHAI FENG Effective date: 20150416 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Baoji Inventor before: Di Feng |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHAI FENG TO: LI BAOJI Free format text: CORRECT: ADDRESS; FROM: 043400 LINFEN, SHAANXI PROVINCE TO: 030024 TAIYUAN, SHAANXI PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150416 Address after: 030024 No. 19 West Main Street, Wan Berlin District, Shanxi, Taiyuan, Yingze Applicant after: Li Baoji Address before: 043400 Shanxi city of Linfen province Quwo County Street Applicant before: Di Feng |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xiu Xiaoguang Inventor after: Hou Rongyao Inventor after: Sun Yan Inventor before: Li Baoji |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160627 Address after: Shibei District People's road 266033 Shandong city of Qingdao province No. 4 Applicant after: Qingdao Hiser Medical Center Address before: 030024 No. 19 West Main Street, Wan Berlin District, Shanxi, Taiyuan, Yingze Applicant before: Li Baoji |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 Termination date: 20170430 |